ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 212 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,336,313 | +2.8% | 245,195 | +26.6% | 0.01% | +16.7% |
Q2 2023 | $1,299,948 | -56.3% | 193,733 | -42.4% | 0.01% | -60.0% |
Q1 2023 | $2,971,887 | -4.6% | 336,567 | -17.4% | 0.02% | -11.8% |
Q4 2022 | $3,114,324 | +45.0% | 407,634 | +35.1% | 0.02% | +41.7% |
Q3 2022 | $2,148,000 | +23.4% | 301,754 | +40.2% | 0.01% | +33.3% |
Q2 2022 | $1,741,000 | +48.5% | 215,258 | +154.9% | 0.01% | +28.6% |
Q1 2022 | $1,172,000 | +32.3% | 84,456 | +167.3% | 0.01% | +40.0% |
Q4 2021 | $886,000 | +266.1% | 31,593 | +343.8% | 0.01% | +150.0% |
Q3 2021 | $242,000 | -94.5% | 7,118 | -93.4% | 0.00% | -93.5% |
Q2 2021 | $4,412,000 | -18.1% | 107,977 | -19.3% | 0.03% | -20.5% |
Q1 2021 | $5,387,000 | -59.2% | 133,794 | -40.1% | 0.04% | -64.9% |
Q4 2020 | $13,206,000 | +172.9% | 223,339 | +124.5% | 0.11% | +177.5% |
Q3 2020 | $4,839,000 | +356.5% | 99,503 | +354.4% | 0.04% | +233.3% |
Q2 2020 | $1,060,000 | – | 21,900 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
Triatomic Management LP | 130,805 | $999,350 | 0.84% |
Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |